TY - JOUR
T1 - Subjective cognitive decline and self-reported sleep problems
T2 - The SCIENCe project
AU - Exalto, Lieza G.
AU - Hendriksen, Heleen M. A.
AU - Barkhof, Frederik
AU - van den Bosch, Karlijn A.
AU - Ebenau, Jarith L.
AU - van Leeuwenstijn-Koopman, Mardou
AU - Prins, Niels D.
AU - Teunissen, Charlotte E.
AU - Visser, Leonie N. C.
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
N1 - Funding Information: The VUmc Alzheimer's Center is supported by Alzheimer's Nederland (PhS) and Stichting VUmc fonds, and the clinical database structure was developed with funding from Stichting Dioraphte. Research of the VUmc Alzheimer's Center is part of the neurodegeneration research program of Neuroscience Amsterdam. The SCIENCe cohort receives funding from Gieskes‐Strijbis Fonds and stichting Dioraphte. LGE is supported by is supported by Alzheimer's Nederland WE.03‐2019‐15 and H2020 grant n. 847749 . FB is supported by the NIHR biomedical research centre at UCLH. Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer's Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer's Netherlands, Alzheimer's Association. CET is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes‐Strijbisfonds. IV is appointed on a research grant by Alzheimer's Nederland (NL‐17004). CET has a collaboration contract with ADx Neurosciences and Quanterix, performed contract research or received grants from AC‐Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. LV is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). She is also supported by a fellowship grant received from Alzheimer's Nederland (WE.15‐2019‐05). Payments were made to the institution. PhS is recipient of JPND‐EURO‐FINGERS (ZonMW #733051102). Research programs of WF have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer's Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - We aim to investigate the frequency and type of sleep problems in memory clinic patients with subjective cognitive decline (SCD) and their association with cognition, mental health, brain magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) biomarkers. Three hundred eight subjects (65 ± 8 years, 44% female) were selected from the Subjective Cognitive Impairment Cohort (SCIENCe) project. All subjects answered two sleep questionnaires, Berlin Questionnaire (sleep apnea) and Pittsburgh Sleep Quality Index (sleep quality) and underwent a standardized memory clinic work-up. One hundred ninety-eight (64%) subjects reported sleep problems, based on 107 (35%) positive screenings on sleep apnea and 162 (53%) on poor sleep quality. Subjects with sleep problems reported more severe depressive symptoms, more anxiety, and more severe SCD. Cognitive tests, MRI, and CSF biomarkers did not differ between groups. Our results suggest that improvement of sleep quality and behaviors are potential leads for treatment in many subjects with SCD to relieve the experienced cognitive complaints.
AB - We aim to investigate the frequency and type of sleep problems in memory clinic patients with subjective cognitive decline (SCD) and their association with cognition, mental health, brain magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) biomarkers. Three hundred eight subjects (65 ± 8 years, 44% female) were selected from the Subjective Cognitive Impairment Cohort (SCIENCe) project. All subjects answered two sleep questionnaires, Berlin Questionnaire (sleep apnea) and Pittsburgh Sleep Quality Index (sleep quality) and underwent a standardized memory clinic work-up. One hundred ninety-eight (64%) subjects reported sleep problems, based on 107 (35%) positive screenings on sleep apnea and 162 (53%) on poor sleep quality. Subjects with sleep problems reported more severe depressive symptoms, more anxiety, and more severe SCD. Cognitive tests, MRI, and CSF biomarkers did not differ between groups. Our results suggest that improvement of sleep quality and behaviors are potential leads for treatment in many subjects with SCD to relieve the experienced cognitive complaints.
KW - Alzheimer's disease
KW - Berlin questionnaire
KW - Pittsburgh Sleep Quality Index
KW - sleep
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85145038368&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12287
DO - https://doi.org/10.1002/dad2.12287
M3 - Article
C2 - 35603141
SN - 2352-8729
VL - 14
SP - e12287
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
IS - 1
M1 - e12287
ER -